Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK.
J Neurol. 2023 Jul;270(7):3464-3474. doi: 10.1007/s00415-023-11629-x. Epub 2023 Mar 27.
Misdiagnosis and delayed diagnosis in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are common. Few studies have systematically evaluated the diagnostic process from symptom onset to death in representative cohorts.
All PSP/CBD cases (n = 28/2) and age-sex matched Parkinson's disease (PD) cases (n = 30) were identified from a UK prospective incident Parkinsonism cohort. Medical and research records were reviewed to compare median times from first index symptom to key diagnostic milestones and the nature/timing of secondary care referral and review.
Index symptoms were similar apart from more tremor in PD (p < 0.001) and more impaired balance (p = 0.008) and falls (p = 0.004) in PSP/CBD. PD was diagnosed a median 0.96 years after index symptom. In PSP/CBD the median times from index symptom to identifying parkinsonism and then including PSP/CBD in the differential diagnosis and the final diagnosis were 1.88, 3.41 and 4.03 years, respectively (all p < 0.001). Survival from symptom onset in PSP/CBD and PD was not significantly different (5.98 vs 6.85 years, p = 0.72). More diagnoses (p < 0.001) were considered in PSP/CBD. Prior to diagnosis, PSP/CBD patients had more recurrent emergency attendances (33.3% vs 10.0%, p = 0.01) and were referred to more specialities than PD (median 5 vs 2). Time to any outpatient referral (0.70 vs 0.03 years, p = 0.025) and to specialist movement disorder review (1.96 vs 0.57 years, p = 0.002) was longer in PSP/CBD.
The duration and complexity of the diagnostic journey were greater in PSP/CBD than age-sex matched PD but can be improved. In this older cohort, there was little difference in survival from symptom onset in PSP/CBD and age-sex matched PD.
在进行性核上性麻痹(PSP)和皮质基底节变性(CBD)的诊断时,误诊和延迟诊断较为常见。很少有研究系统地评估过代表性队列中从症状出现到死亡的诊断过程。
在英国前瞻性帕金森病队列中,我们确定了所有 PSP/CBD 病例(n=28/2)和年龄性别匹配的帕金森病(PD)病例(n=30)。我们回顾了医疗和研究记录,以比较从首发症状到关键诊断里程碑的中位数时间,以及二级保健转诊和复查的性质/时间。
除 PD 中震颤更多(p<0.001)、PSP/CBD 中平衡障碍(p=0.008)和跌倒(p=0.004)更多外,首发症状相似。PD 的诊断中位时间为首发症状后 0.96 年。在 PSP/CBD 中,从首发症状到识别帕金森病,然后将 PSP/CBD 纳入鉴别诊断和最终诊断的中位数时间分别为 1.88、3.41 和 4.03 年(均 p<0.001)。PSP/CBD 和 PD 从症状出现到死亡的生存时间无显著差异(5.98 与 6.85 年,p=0.72)。PSP/CBD 考虑的诊断更多(p<0.001)。在诊断之前,PSP/CBD 患者的急诊就诊次数更多(33.3%与 10.0%,p=0.01),就诊科室多于 PD(中位数 5 与 2)。首次门诊转诊(0.70 与 0.03 年,p=0.025)和专科运动障碍复查(1.96 与 0.57 年,p=0.002)的时间在 PSP/CBD 中更长。
与年龄性别匹配的 PD 相比,PSP/CBD 的诊断过程持续时间更长,复杂性更高,但可以改善。在这个年龄较大的队列中,PSP/CBD 和年龄性别匹配的 PD 从症状出现到死亡的生存时间几乎没有差异。